Cargando…

Melatonin and urological cancers: a new therapeutic approach

Urological cancers are responsible for thousands of cancer-related deaths around the world. Despite all developments in therapeutic approaches for cancer therapy, the absence of efficient treatments is a critical and vital problematic issue for physicians and researchers. Furthermore, routine medica...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehrzadi, Mohammad Hossein, Hosseinzadeh, Azam, Juybari, Kobra Bahrampour, Mehrzadi, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488244/
https://www.ncbi.nlm.nih.gov/pubmed/32943992
http://dx.doi.org/10.1186/s12935-020-01531-1
_version_ 1783581654643638272
author Mehrzadi, Mohammad Hossein
Hosseinzadeh, Azam
Juybari, Kobra Bahrampour
Mehrzadi, Saeed
author_facet Mehrzadi, Mohammad Hossein
Hosseinzadeh, Azam
Juybari, Kobra Bahrampour
Mehrzadi, Saeed
author_sort Mehrzadi, Mohammad Hossein
collection PubMed
description Urological cancers are responsible for thousands of cancer-related deaths around the world. Despite all developments in therapeutic approaches for cancer therapy, the absence of efficient treatments is a critical and vital problematic issue for physicians and researchers. Furthermore, routine medical therapies contribute to several undesirable adverse events for patients, reducing life quality and survival time. Therefore, many attempts are needed to explore potent alternative or complementary treatments for great outcomes. Melatonin has multiple beneficial potential effects, including anticancer properties. Melatonin in combination with chemoradiation therapy or even alone could suppress urological cancers through affecting essential cellular pathways. This review discusses current evidence reporting the beneficial effect of melatonin in urological malignancies, including prostate cancer, bladder cancer, and renal cancer.
format Online
Article
Text
id pubmed-7488244
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74882442020-09-16 Melatonin and urological cancers: a new therapeutic approach Mehrzadi, Mohammad Hossein Hosseinzadeh, Azam Juybari, Kobra Bahrampour Mehrzadi, Saeed Cancer Cell Int Review Urological cancers are responsible for thousands of cancer-related deaths around the world. Despite all developments in therapeutic approaches for cancer therapy, the absence of efficient treatments is a critical and vital problematic issue for physicians and researchers. Furthermore, routine medical therapies contribute to several undesirable adverse events for patients, reducing life quality and survival time. Therefore, many attempts are needed to explore potent alternative or complementary treatments for great outcomes. Melatonin has multiple beneficial potential effects, including anticancer properties. Melatonin in combination with chemoradiation therapy or even alone could suppress urological cancers through affecting essential cellular pathways. This review discusses current evidence reporting the beneficial effect of melatonin in urological malignancies, including prostate cancer, bladder cancer, and renal cancer. BioMed Central 2020-09-10 /pmc/articles/PMC7488244/ /pubmed/32943992 http://dx.doi.org/10.1186/s12935-020-01531-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Mehrzadi, Mohammad Hossein
Hosseinzadeh, Azam
Juybari, Kobra Bahrampour
Mehrzadi, Saeed
Melatonin and urological cancers: a new therapeutic approach
title Melatonin and urological cancers: a new therapeutic approach
title_full Melatonin and urological cancers: a new therapeutic approach
title_fullStr Melatonin and urological cancers: a new therapeutic approach
title_full_unstemmed Melatonin and urological cancers: a new therapeutic approach
title_short Melatonin and urological cancers: a new therapeutic approach
title_sort melatonin and urological cancers: a new therapeutic approach
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488244/
https://www.ncbi.nlm.nih.gov/pubmed/32943992
http://dx.doi.org/10.1186/s12935-020-01531-1
work_keys_str_mv AT mehrzadimohammadhossein melatoninandurologicalcancersanewtherapeuticapproach
AT hosseinzadehazam melatoninandurologicalcancersanewtherapeuticapproach
AT juybarikobrabahrampour melatoninandurologicalcancersanewtherapeuticapproach
AT mehrzadisaeed melatoninandurologicalcancersanewtherapeuticapproach